-

Bruker Secures Multi-Year Contracts for Explosives and Chemical Trace Detection in Aviation and Defense Sectors

New agreements with major airports and airlines reflect growing demand for Bruker’s trace detection technologies, with a focus on Europe

ETTLINGEN, Germany--(BUSINESS WIRE)--Bruker Corporation (Nasdaq: BRKR) today announced the signing of multiple new contracts and framework agreements for its explosives and chemical trace detection solutions, accessories, consumables, and service offerings. Finalized throughout 2025, these agreements represent a total order volume of over $27 million year-to-date in 2025, supporting customers in the aviation security and defense industry to enhance threat detection capabilities.

The contracts include deployments of Bruker’s explosive trace detection (ETD) solutions at major international airports and air cargo facilities, as well as chemical reconnaissance solutions for homeland security and defense agencies. Confirmed customers include Brussels Airport Company NV, which awarded Bruker a seven-year framework agreement for the delivery and third-line maintenance of 80 ETD units, along with training, consumables, spare parts, and a centralized management software platform. Additional confirmed deployments include more than 200 ETD units across Scandinavian airports, 74 units at Saudi Arabian airports, and 17 units to Incheon International Airport in South Korea. Further earlier deployments at key European hubs in Frankfurt, Geneva, and Zürich strengthen Bruker’s footprint in critical aviation security infrastructure. In the defense sector, Bruker has received confirmed orders for over 500 chemical reconnaissance systems from a Central European country’s Ministry of Defense.

Bruker’s DE-tector flex systems are designed for high-throughput screening of passengers and cargo, offering industry-leading low false alarm rates, intuitive operation, and minimal maintenance. The RAID-XP and RAPIDplus chemical detection systems are used in mobile reconnaissance missions and fixed installations, supporting homeland security and defense applications.

“Our Detection Business continues to expand its global footprint with significant wins across multiple safety and security domains,” said Dr. Andreas Kamlowski, President of Bruker Optics. “These contracts reflect our strategic momentum and underscore our commitment to supporting public safety through advanced detection technologies.”

Bruker’s Detection business remains focused on three strategic pillars: airline safety, airport security, and chemical reconnaissance. The company expects continued growth in these areas, supported by rising global demand for integrated CBRN (Chemical, Biological, Radiological, Nuclear, and Explosive) solutions and next-generation ETD systems. These technologies are part of a comprehensive portfolio supporting CBRNE threat detection, safety, and environmental monitoring. More information on Bruker’s solutions for security, civil protection, and defense applications can be found at: https://www.bruker.com/en/products-and-solutions/cbrne-detectors.html.

About Bruker Corporation – Leader of the Post-Genomic Era (Nasdaq: BRKR)

Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker’s high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity, and customer success in post-genomic life science molecular and cell biology research, in applied and biopharma applications, in microscopy and nanoanalysis, as well as in industrial and cleantech research, and next-gen semiconductor metrology in support of AI. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit www.bruker.com.

Contacts

Investor Contact:
Joe Kostka
Director - Investor Relations
Bruker Corporation
T: +1 (978) 313-5800
E: Investor.Relations@bruker.com

Media Contact:
Natalie Spahl
Head of Global Marketing
Bruker BioSpin
T: +49 173 9662425
E: Natalie.spahl@bruker.com

Bruker Corporation

NASDAQ:BRKR

Release Versions
$Cashtags
Hashtags

Contacts

Investor Contact:
Joe Kostka
Director - Investor Relations
Bruker Corporation
T: +1 (978) 313-5800
E: Investor.Relations@bruker.com

Media Contact:
Natalie Spahl
Head of Global Marketing
Bruker BioSpin
T: +49 173 9662425
E: Natalie.spahl@bruker.com

Social Media Profiles
More News From Bruker Corporation

RI Research Instruments Announces Major Orders for Enabling Technology for the Gamma-Ray Source of the Extreme Light Infrastructure (ELI)

BERGISCH GLADBACH, Germany--(BUSINESS WIRE)--RI Research Instruments, a company that is majority-owned by Bruker Corporation (Nasdaq: BRKR), today announced orders for key components and enabling subsystems for the research gamma ray source of the Extreme Light Infrastructure – Nuclear Physics (ELI-NP) at the Horia Hulubei National Institute of Physics and Nuclear Engineering (IFIN-HH) in Romania. The total value of these ELI contracts is approximately €35 million (more than USD $40 million), w...

Bruker Announces Orders for High-Performance Magnetic Resonance Systems for Materials and Life-Science Research from Leading European Institutions

ETTLINGEN, Germany--(BUSINESS WIRE)--Bruker Corporation (Nasdaq: BRKR) today announced several significant European orders for high-performance magnetic resonance systems from three leading research institutions in France and Germany: In the summer, École Normale Supérieure (ENS-PSL) in Paris, France ordered a novel NMR relaxometry system to be used alongside its recently acquired 900 MHz NMR spectrometer. This unique capability will empower the investigation of the molecular dynamics of protei...

Bruker Announces the Addition of Diagnostics Industry Leader Jack Phillips to its Board of Directors as of January 2026

BILLERICA, Mass.--(BUSINESS WIRE)--Bruker Corporation (Nasdaq: BRKR) today announced that its Board of Directors has added Jack J. Phillips to serve on its board of directors, effective as of January 1st, 2026. Mr. Phillips is a senior healthcare industry executive with over 30 years of leadership experience in the diagnostics industry. Frank H. Laukien, chairman, president and CEO of Bruker Corporation, stated: “Bruker is delighted to add Jack to our board of directors. His broad and deep diag...
Back to Newsroom